Showing 1351-1360 of 3001 results for "".
- Reassuring Evidence of Antibody Response During Treatment With Cladribine for Multiple Sclerosishttps://practicalneurology.com/news/reassuring-evidence-of-antibody-response-during-treatment-with-cladribine-for-multiple-sclerosis/2469511/Individuals with relapsing multiple sclerosis (MS) who were vaccinated against varicella zoster virus (VZV; n=3) before, or seasonal influenza (n=12) after a first course of treatment with cladribine (MAVENCLAD; EMD Serono; Rockland, MA) retained effective antibody titers against those viruses. I
- European Clinical Show Nabiximols Treatment Reduces Spasticity in Multiple Sclerosis Without Affecting Muscle Strength or Walking Speedhttps://practicalneurology.com/news/european-clinical-show-nabiximols-treatment-reduces-spasticity-in-multiple-sclerosis-without-affecting-muscle-strength-or-walking-speed/2469429/Data from 3 European randomized placebo-controlled clinical trials of nabiximols (Sativex; GW Pharmaceuticals, Carlsbad, CA) for spasticity in multiple sclerosis (MS) were presented at the American Academy of Physical Medicine and Rehabilitation (AAPMR) Annual Assembley. Nabiximols is derived fro
- Cannabis-Derived Nabiximols Well-Tolerated and Effective for Spasticity in Multiple Sclerosishttps://practicalneurology.com/news/cannabis-derived-nabiximols-well-tolerated-and-effective-for-spasticity-in-multiple-sclerosis/2469385/Nabiximols (Greenwich Biosciences, Carlsbad, CA) is approved for use as Sativex in over 25 countries, but not the US, for treatment of spasticity in multiple sclerosis (MS). Nabiximols is a chemically complex extract of the cannabis plant, consistently produced under controlled conditions and adm
- Expanded Disability Status Scale Available on Digital Platformhttps://practicalneurology.com/news/expanded-disability-status-scale-available-on-digital-platform/2469321/The proprietary platform (eCOA Pathway; VeraSci, Durham, NC) has been expanded to fully integrate the Expanded Disability Status Scale (EDSS) assessment and Neurostatus data clarification services for MS trials. VeraSci partnered with Dr. Marcus D'Souza and professor Ludwig Kappos at Neurosta
- Enrollment Begins for Phase 1b Clinical Trial of T-cell Immunotherapy for Progressive Multiple Sclerosishttps://practicalneurology.com/news/enrollment-begins-for-phase-1b-clinical-trial-of-t-cell-immunotherapy-for-progressive-multiple-sclerosis/2469303/The first participant has been enrolled in a phase 1b study of the allogeneic EBV T-cell immunotherapy (ATA188; Atara Biotherapeutics, South San Francisco, CA), for individuals with progressive forms of multiple sclerosis (MS). Participants in clinical sites across the US and Australia
- New Social Networking Platform for the Multiple Sclerosis Communityhttps://practicalneurology.com/news/new-social-networking-platform-for-the-multiple-sclerosis-community/2469254/A new free anonymous AI-powered social networking and navigation platform, BelongMS (Belong.Life, New York, NY), has been launched for individuals with multiple sclerosis (MS), caregivers, and healthcare professionals. The app can be downloaded for Android and iOS. The new app follows t
- Registry Database for COVID-19 in People With Multiple Sclerosis Createdhttps://practicalneurology.com/news/registry-database-for-covid-19-in-people-with-multiple-sclerosis-created/2469229/The Consortium of Multiple Sclerosis Centers (CMSC) and the National Multiple Sclerosis Society have worked together to create COViMS, a new North American database to capture COVID-19 infections in individuals with multiple sclerosis (MS) and related diseases. This joint effort will capture info
- Nanocatalytic Gold Therapy Well Tolerated in Clinical Trial for Multiple Sclerosishttps://practicalneurology.com/news/nanocatalytic-gold-therapy-well-tolerated-in-clinical-trial-for-multiple-sclerosis/2469174/Preliminary data from the randomized placebo-controlled phase 2 VISIONARY-MS trial (NCT03536559) of nanocatalytic gold therapy (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) suggest the drug is well tolerated. Preliminary blinded da
- Update to MRI Protocols for Multiple Sclerosis from the Consortium of Multiple Sclerosis Centershttps://practicalneurology.com/news/update-to-mri-protocols-for-multiple-sclerosis-from-the-consortium-of-multiple-sclerosis-centers/2469172/The Consortium of Multiple Sclerosis Centers (CMSC) has revised MRI protocols for multiple sclerosis (MS). The updated Standardized Brain MRI Protocol includes • Mandatory axial FLAIR, sagittal FLAIR, and axial T2 imaging • Use of
- Machine Learning Models to Aid Early Accurate Diagnosis of Multiple Sclerosishttps://practicalneurology.com/news/machine-learning-models-to-aid-early-accurate-diagnosis-of-multiple-sclerosis/2469171/Machine learning models performed with sensitivity and specificity for distinguishing between the brains of people with and without multiple sclerosis (MS). These models were constructed using a medical device software program that computes volumetric brain measurement from MRIs (NeuroQuant 3.0;